TXG vs. CRSP

Last updated Aug 4, 2026

TXG (10x Genomics, Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. Both are in the Healthcare sector — TXG in Health Information Services, CRSP in Biotechnology. Over the past 5 years, TXG returned -23.95%/yr vs -16.84%/yr for CRSP. Their 0.47 correlation means their historical movements had little consistent relationship.

Performance

TXG vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TXG achieves a 188.23% return, which is significantly higher than CRSP's -5.47% return.

TXG

• 1D: -0.55%
• 1M: 20.51%
• 6M: 135.64%
• YTD: 188.23%
• 1Y: 259.40%
• 3Y*: -5.69%
• 5Y*: -23.95%
• 10Y*: —
• ALL TIME*: -1.99%

CRSP

• 1D: 3.29%
• 1M: -17.49%
• 6M: -3.39%
• YTD: -5.47%
• 1Y: -11.62%
• 3Y*: -0.92%
• 5Y*: -16.84%
• 10Y*: —
• ALL TIME*: 12.99%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
CRSP CRISPR Therapeutics AG	$76.39M	$84.18M	$88.74M
TXG 10x Genomics, Inc.	$125.19M	$129.80M	$108.79M

TXG vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TXG 10x Genomics, Inc.	188.23%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	41.20%
CRSP CRISPR Therapeutics AG	-5.47%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	27.23%

Correlation

The correlation between TXG and CRSP is 0.35, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.35
Correlation (3Y) Balances recent behavior with more history.	0.43
Correlation (5Y) Shows whether the relationship held over a longer period.	0.48
Correlation (All Time) Calculated using the full available price history since Sep 12, 2019	0.47

The correlation between TXG and CRSP shifts across timeframes, from 0.35 (1 year) to 0.48 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TXG : $5.97B CRSP : $4.78B
EPS TXG : -$0.18 CRSP : -$4.83
PS Ratio TXG : 9.34 CRSP : 345.90
PB Ratio TXG : 7.41 CRSP : 2.74
Total Revenue (TTM) TXG : $638.78M CRSP : $13.39M
Gross Profit (TTM) TXG : $444.61M CRSP : -$163.39M
EBITDA (TTM) TXG : -$5.89M CRSP : -$460.77M

Return for Risk

TXG vs. CRSP — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

TXG

TXG Risk / Return Rank: 97
TXG Sharpe Ratio Rank: 98
TXG Sortino Ratio Rank: 97
TXG Omega Ratio Rank: 94
TXG Calmar Ratio Rank: 98
TXG Martin Ratio Rank: 98

CRSP

CRSP Risk / Return Rank: 35
CRSP Sharpe Ratio Rank: 35
CRSP Sortino Ratio Rank: 36
CRSP Omega Ratio Rank: 35
CRSP Calmar Ratio Rank: 35
CRSP Martin Ratio Rank: 36

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

TXG vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	TXG	CRSP	Difference
Sharpe ratio: Return per unit of total volatility	3.74	-0.20	+3.94
Sortino ratio: Return per unit of downside risk	3.91	0.12	+3.80
Omega ratio: Gain probability vs. loss probability	1.44	1.01	+0.43
Calmar ratio: Return relative to maximum drawdown	9.32	-0.28	+9.60
Martin ratio: Return relative to average drawdown	22.43	-0.43	+22.85

TXG vs. CRSP - Sharpe Ratio Comparison

The current TXG Sharpe Ratio is 3.74, which is higher than the CRSP Sharpe Ratio of -0.20. The chart below compares the historical Sharpe Ratios of TXG and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

TXG vs. CRSP - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for TXG and CRSP.

Drawdown Indicators

	TXG	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-96.47%	-85.11%	-11.36%
Max Drawdown (1Y) Largest decline over 1 year	-28.03%	-42.25%	+14.22%
Max Drawdown (3Y) Largest decline over 3 years	-87.59%	-64.91%	-22.68%
Max Drawdown (5Y) Largest decline over 5 years	-96.26%	-77.31%	-18.95%
Current Drawdown Current decline from peak	-76.77%	-76.40%	-0.37%
Average Drawdown Average peak-to-trough decline	-60.11%	-49.60%	-10.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.62%	27.35%	-15.73%

Volatility

TXG vs. CRSP - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 22.64% compared to CRISPR Therapeutics AG (CRSP) at 12.76%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TXG	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.64%	12.76%	+9.88%
Volatility (6M) Calculated over the trailing 6-month period	50.48%	42.20%	+8.28%
Volatility (1Y) Calculated over the trailing 1-year period	70.01%	58.84%	+11.17%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.39%	60.68%	+8.71%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	67.06%	64.14%	+2.92%

Dividends

TXG vs. CRSP - Dividend Comparison

Neither TXG nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both TXG and CRSP in my portfolio?

TXG and CRSP have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TXG or CRSP?

TXG has higher volatility (22.64%) compared to CRSP (12.76%). In terms of maximum drawdown, TXG dropped -96.47% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

TXG currently has the higher Sharpe Ratio (3.74 vs -0.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.